Veru Inc. (VERU): Price and Financial Metrics


Veru Inc. (VERU): $5.79

0.29 (+5.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VERU POWR Grades

  • VERU scores best on the Quality dimension, with a Quality rank ahead of 40.69% of US stocks.
  • VERU's strongest trending metric is Growth; it's been moving down over the last 178 days.
  • VERU's current lowest rank is in the Growth metric (where it is better than 1.16% of US stocks).

VERU Stock Summary

  • VERU's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.18 -- higher than only 2.58% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 145.53%, VERU INC's debt growth rate surpasses 91.08% of about US stocks.
  • Over the past twelve months, VERU has reported earnings growth of -5,108.95%, putting it ahead of only 0.35% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VERU INC are BCDA, VLN, CRDF, CRBU, and CLGN.
  • VERU's SEC filings can be seen here. And to visit VERU INC's official web site, go to www.verupharma.com.

VERU Valuation Summary

  • VERU's EV/EBIT ratio is -8.1; this is 193.1% lower than that of the median Healthcare stock.
  • Over the past 243 months, VERU's price/sales ratio has gone up 4.9.

Below are key valuation metrics over time for VERU.

Stock Date P/S P/B P/E EV/EBIT
VERU 2022-12-02 8.4 3.8 -9.4 -8.1
VERU 2022-12-01 8.4 3.8 -9.3 -8.1
VERU 2022-11-30 8.7 3.9 -9.7 -8.5
VERU 2022-11-29 8.4 3.8 -9.4 -8.2
VERU 2022-11-28 8.3 3.7 -9.2 -8.0
VERU 2022-11-25 8.6 3.8 -9.6 -8.3

VERU Growth Metrics

    Its year over year revenue growth rate is now at 20.86%.
  • The 3 year price growth rate now stands at 471.52%.
  • The 3 year revenue growth rate now stands at 151.39%.
VERU's revenue has moved up $20,608,794 over the prior 33 months.

The table below shows VERU's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 52.41218 -27.43297 -47.04789
2022-03-31 60.46558 -26.24523 -27.54518
2021-12-31 60.77767 -24.88806 -16.21333
2021-09-30 61.25953 -15.57102 7.394374
2021-06-30 57.36225 -15.10567 -0.143691
2021-03-31 50.02842 1.067131 -0.476205

VERU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERU has a Quality Grade of C, ranking ahead of 60.52% of graded US stocks.
  • VERU's asset turnover comes in at 0.473 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • INSM, MNKD, and REPH are the stocks whose asset turnover ratios are most correlated with VERU.

The table below shows VERU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.473 0.788 0.038
2021-03-31 0.540 0.756 0.193
2020-12-31 0.760 0.737 0.295
2020-09-30 0.750 0.723 -0.912
2020-06-30 0.691 0.684 -0.376
2020-03-31 0.716 0.696 -0.365

VERU Price Target

For more insight on analysts targets of VERU, see our VERU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.40 Average Broker Recommendation 1.3 (Strong Buy)

VERU Stock Price Chart Interactive Chart >

Price chart for VERU

VERU Price/Volume Stats

Current price $5.79 52-week high $24.55
Prev. close $5.50 52-week low $4.34
Day low $5.38 Volume 7,243,430
Day high $6.53 Avg. volume 10,610,241
50-day MA $9.66 Dividend yield N/A
200-day MA $11.09 Market Cap 464.05M

Veru Inc. (VERU) Company Bio


Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.


VERU Latest News Stream


Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream


Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Veru Q4 2022 Earnings Conference Call On December 5, 2022 At 08:00 AM ET

Veru (NASDAQ: VERU ) will host a conference call at 08:00 AM ET on December 5, 2022, to discuss Q4 2022 earnings results. How to Attend Veru (VERU) Conference Call Follow this link to access the live webcast. To listen to the call, dial 1-800-341-1602 (US) or 1-412-902-6706 (International) What Is an Earnings Conference … Full story available on Benzinga.com

Benzinga | November 29, 2022

Veru Inc. (VERU) can excel with these strategies

The share price of Veru Inc. (NASDAQ:VERU) rose to $5.61 per share on Friday from $5.51. While Veru Inc. has overperformed by 1.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERU fell by -28.26%, with highs and lows ranging from $24.55 to $4.34, whereas the […]

US Post News | November 28, 2022

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2022, at 8:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year ended September 30, 2022 financial results and provide a business update.

GlobeNewswire | November 28, 2022

Veru Inc. (VERU) Analyst Thoughts: How High Can It Go?

Veru Inc. (NASDAQ:VERU) at last check was buoying at $5.49 on Friday, November 25, with a fall of -0.36% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.51 and 5Y monthly beta was reading -0.20 with its price kept floating in … Veru Inc. (VERU) Analyst Thoughts: How High Can It Go? Read More »

Stocks Register | November 25, 2022

Is It Too Late to Buy Veru Stock?

The negative impact of its COVID-19 program faltering will soon be in the past.

The Motley Fool | November 23, 2022

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -44.06%
3-mo -60.32%
6-mo -62.16%
1-year -4.46%
3-year 155.07%
5-year 473.27%
YTD -1.70%
2021 -31.91%
2020 158.21%
2019 139.29%
2018 22.81%
2017 25.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7704 seconds.